Consolidated Statements of Comprehensive Loss (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Revenues:
Clinical treatment programs	$ 76	$ 42
Total revenues	76	42
Costs and expenses:
Production/cost of goods sold	323	191
Research and development	2,326	2,336
General and administrative	2,539	2,077
Total costs and expenses	5,188	4,604
Operating loss	(5,112)	(4,562)
Interest expense	(3)	(5)
Interest and other income	153	181
Gain from sale of income tax net operating losses	1,126	686
Redeemable warrants valuation adjustment	0	89
Net loss	(3,836)	(3,611)
Other Comprehensive Income (Loss):
Unrealized gain on marketable securities	21	45
Reclassification adjustments for impairment losses included in net loss	0	(9)
Net comprehensive loss	$ (3,815)	$ (3,575)
Basic and diluted loss per share (usd per share)	$ (0.02)	$ (0.02)
Weighted average shares outstanding, basic and diluted (shares)	176,730,956	166,806,729